Seeking Alpha

Steve Rosenman's  Instablog

Steve Rosenman
Send Message
Mr. Rosenman has nearly 15-years executive experience in the health and wellness sectors, including weight loss, cosmetics skincare and nutrition, both Rx and OTC. Expertise areas include strategic market and product planning and corporate development (evaluation, recommendation and execution of... More
  • Amarin's SNDA For Anchor WILL BE APPROVED ON TIME, PERIOD 17 comments
    May 24, 2013 1:00 PM | about stocks: AMRN

    AF is a lower than the piece of dirt caught in my shoe treads. Anchor will be approved for mixed. lip and there is nothing he can do about it. New flash AF, mixed lip indication is NOT for reducing cardio events, its for lower trigs, and that is what it does, period. FDA will approve the drug for its APPLIED FOR INDICATION.

    And, if we are throwing out predictions, mine is that Reduce It will be successful for reducing cardio events too.

    Stocks: AMRN
Back To Steve Rosenman's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (17)
Track new comments
  • Danburydude
    , contributor
    Comments (106) | Send Message
     
    I give an 'atta boy ' to the hit blogger. He had to come up with some new material. Now he has a new drum to bang over the next few months. Same old noise, different drum.
    I do want to point out that the chairman of the FDA is named Margaret Hamburg. Not someone who campaigned for it back in 2009, hint hint. It is hard to justify a FDA chairman that secretly tapes meetings , even in this current political environment.
    All in all, this makes for good entertainment on a slow Friday.
    24 May 2013, 02:03 PM Reply Like
  • CarolinaCowboy
    , contributor
    Comments (29) | Send Message
     
    Welcome back Steve! Thanks for setting AF straight!
    24 May 2013, 02:47 PM Reply Like
  • coopman98
    , contributor
    Comments (69) | Send Message
     
    steve, what is so frustrating is that this guy gets away with coming out with a hit piece on a friday before market and weekly options expire so someone who can make alot of dough and this manipulation of the stock price goes unnoticed by the SEC
    24 May 2013, 03:10 PM Reply Like
  • johnnybio
    , contributor
    Comments (23) | Send Message
     
    I know the world revolves around Amarin...

     

    Please explain how writing an article that expresses one's opinion is manipulation?

     

    Using your flawless logic, there is no difference between that article and the numerous articles claiming a buyout is happening for $30+? In fact, the stock price moved ~2% after Friday's article, but previous positive articles from another author have caused movements of ~4%.

     

    I would love to hear how someone was going to make a lot of dough yesterday trading weekly call options considering the weak volume, lack of a catalyst, and overall biotech sector being down/flat.

     

    I'm sure this is at the very top of the SEC's list though. Insider trading and constant monitoring of financial statements are minor issues in comparison to this.
    25 May 2013, 05:06 AM Reply Like
  • Pirateescapee
    , contributor
    Comments (109) | Send Message
     
    Steve - Things must not be going well for AF. His efforts to gain attention are becoming more and more desperate. The next 6 months should prove very interesting. What next? LOL.
    24 May 2013, 03:11 PM Reply Like
  • homebuilder_watcher
    , contributor
    Comments (93) | Send Message
     
    I agree with your conclusion on all counts, ANCHOR being approved, REDUCE IT being proven and on AF.
    24 May 2013, 05:49 PM Reply Like
  • region
    , contributor
    Comments (4) | Send Message
     
    great info.. thanks again.. I wish JZ will lower the hammer on AF..
    24 May 2013, 05:49 PM Reply Like
  • Jolk
    , contributor
    Comments (216) | Send Message
     
    Don't forget the equally important reduction of cardio markers that were included in the SPA as a secondary endpoint...

     

    http://seekingalpha.co...

     

    lp-PLA2, hsCRP,etc
    24 May 2013, 10:31 PM Reply Like
  • Solana Partners
    , contributor
    Comments (36) | Send Message
     
    Adam will keep rocking the boat and Amarin remains silent.
    25 May 2013, 03:50 PM Reply Like
  • naivestock
    , contributor
    Comment (1) | Send Message
     
    I agree
    26 May 2013, 03:48 PM Reply Like
  • Pirateescapee
    , contributor
    Comments (109) | Send Message
     
    Steve - Any thoughts on the AZN acquisition of Omthera? I don't get it for all the obvious reasons. What am I missing?
    28 May 2013, 07:19 AM Reply Like
  • golfstud
    , contributor
    Comments (54) | Send Message
     
    steve,

     

    I did not get a chance to listen to the update today but per yahoo board sounds like an advisory commitee has been set up to make a non binding recommendation on anchor. Any thoughts on this being good (approval by December or earlier) or bad (maybe possible no approval). Just curious on your take. Thanks.
    6 Jun 2013, 11:06 AM Reply Like
  • Steve Rosenman
    , contributor
    Comments (785) | Send Message
     
    Author’s reply » will be given the go, they are under SPA.
    8 Jun 2013, 04:52 PM Reply Like
  • golfstud
    , contributor
    Comments (54) | Send Message
     
    Just listened to max macaluso from motley fool and he says basically a coin toss on anchor approval, any comments steve as he seems pretty knowledgable? Thanks
    20 Jun 2013, 06:27 AM Reply Like
  • Jolk
    , contributor
    Comments (216) | Send Message
     
    Is he saying delay until REDUCE-IT results or outright rejected?

     

    If they delay till REDUCE-IT, then generic Lovaza will be the cheapest Off-label omega 3 that will be prescribed to ANCHOR patients.

     

    What is the point of delaying? What if REDUCE-IT is a grand slam success? Will they risk that?

     

    FDA: "Yeah, we could have approved a safe and effective treatment a few years early and we could have saved patient's lives, but we listened to the short bashers instead"

     

    Vascepa lowers cardio biomarkers either with statin, or on its own... Why deny the use of an effective treatment that Dr.s are already treating, eg to lower hsCRP, lp-PLA2, apo B, apo CIII, Trigs, etc.
    20 Jun 2013, 11:20 AM Reply Like
  • Steve Rosenman
    , contributor
    Comments (785) | Send Message
     
    Author’s reply » If you think Max is credible, than the answer is easy. It will be 100% approved :-)
    28 Jun 2013, 05:53 PM Reply Like
  • bakemann
    , contributor
    Comments (33) | Send Message
     
    A.F's thinking is basically if my try's are 500 my doc. should give me V
    but if there 499 well lets hold on for Reduce-it results
    No really taking out the sarcasm , Why would the FDA allow V for 500+
    patients but 300 or 400 not. I'm shocked peaple are even debating approval!
    30 Jun 2013, 07:02 PM Reply Like
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.